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Abstract
Background: Low doses of dopamine agonists (DA) and levodopa are effective in the treatment of restless legs
syndrome (RLS). A range of impulse control and compulsive behaviours (ICBs) have been reported following the
use of DAs and levodopa in patients with Parkinson’s disease. With this study we sought to assess the cross-
sectional prevalence of impulse control behaviours (ICBs) in restless legs syndrome (RLS) and to determine factors
associated with ICBs in a population cohort in Germany.
Methods: Several questionnaires based on validated and previously used instruments for assessment of ICBs were
mailed out to patients being treated for RLS. Final diagnoses of ICBs were based on stringent diagnostic criteria
after psychiatric interviews were performed.
Results: 10/140 RLS patients of a clinical cohort (7.1%) were finally diagnosed with ICBs, 8 of 10 on dopamine
agonist (DA) therapy, 2 of 10 on levodopa. 8 of the 10 affected patients showed more than one type of abnormal
behaviour. Among those who responded to the questionnaires 6/140 [4.3%] revealed binge eating, 5/140 [3.6%]
compulsive shopping, 3/140 [2.1%] pathological gambling, 3/140 [2.1%] punding, and 2/140 [1.4%] hypersexuality
in psychiatric assessments. Among those who did not respond to questionnaires, 32 were randomly selected and
interviewed: only 1 patient showed positive criteria of ICBs with compulsive shopping and binge eating. ICBs were
associated with higher DA dose (p = 0.001), younger RLS onset (p = 0.04), history of experimental drug use (p =
0.002), female gender (p = 0.04) and a family history of gambling disorders (p = 0.02), which accounted for 52% of
the risk variance.
Conclusion: RLS patients treated with dopaminergic agents and dopamine agonists in particular, should be
forewarned of potential side effects. A careful history of risk factors should be taken.
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Background
An increasing awareness of restless legs syndrome (RLS)
[1] has led to a higher number of patients being treated
with dopaminergic agents. Although a dopaminergic defi-
cit has not been demonstrated in RLS [2], it is believed
that an imbalance of the diencephalo-spinal dopaminer-
gic system exists [3] and that it interacts with the iron
metabolism [4]. Low doses of dopamine agonists (DA)
are effective for improving sleep disturbances, daytime
symptoms and quality of life of RLS sufferers [5]. The
DAs ropinirole, pramipexole and rotigotine transdermal
patch are licensed for treating RLS in most European
countries and–except for rotigotine–in the US. In
Germany, Austria and Switzerland levodopa/benserazide
has also received regulatory approval for RLS therapy.
A range of impulse control and compulsive behaviours
(ICBs) have been reported following the use of DAs and
levodopa in patients with Parkinson’s disease. DAs are
particularly associated with pathological gambling, com-
pulsive shopping, hypersexuality and binge eating [6-10].
* Correspondence: ctrenkwalder@gmx.de
2Paracelsus-Elena-Hospital, Center of Parkinsonism and Movement Disorders,
Kassel, Germany
Full list of author information is available at the end of the article
Voon et al. BMC Neurology 2011, 11:117
http://www.biomedcentral.com/1471-2377/11/117
© 2011 Voon et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Systematic studies on pathological gambling have been
conducted in Italy [7] and the United Kingdom [9] but
none have been reported in Germany. Hypersexuality has
been reported with levodopa monotherapy, although it is
more likely to occur on DAs. Binge eating has also been
associated with DAs [10,11]. Punding has been variably
associated with levodopa and DAs [12-14]. Compulsive
medication use has been associated with levodopa
[15,16]. Such behaviours are variably associated with ear-
lier age of disease onset, a personal or family history of
gambling or alcohol use disorders, smoking, greater
experimental drug use, and higher novelty seeking and
impulsivity scores [10,14,15,17,18]. The objectives of this
study were to assess the cross-sectional prevalence of
ICBs in RLS using stringent diagnostic criteria and to
determine factors associated with ICBs in a population
cohort in Germany.
Methods
The questionnaires used in this study were based on dif-
ferent screening tools that had either been validated in the
general population or had been used in previous studies of
ICBs in Parkinson’s disease. These screening tools were:
1. The South Oaks Gambling Screen was used to
assess gambling [19].
2. A previously published questionnaire for Parkinson’s
disease was used for hypersexuality [6].
3. The Minnesota Impulse Disorders Interview was
used for compulsive shopping [8].
4. Questions adapted from Evans et al.’s question-
naire were used for punding [14].
Associated factors that were also assessed included
experimental drug use, cigarette smoking, alcohol use
and family history of alcohol/substance use and gambling
disorders, and novelty seeking behaviours. The question-
naires were translated into German following recom-
mended rules for translating scales with back translation
from two different translators, and mailed out to all RLS
patients who had consulted at the RLS outpatient clinic
of the Paracelsus-Elena Hospital in Kassel, Germany,
within the previous two years.
All patients were interviewed by an RLS expert (CT)
and their diagnosis confirmed according to the essential
RLS diagnostic criteria, a full history was performed and
a neurological exam made. Patients with low ferritin
levels were included in the sample; ureamic RLS and
other secondary causes of RLS were excluded.
A cut-off for the screening questionnaires was defined
according to previous studies [20]. Patients who scored
above cut-off on the screening questions were contacted
and extensively interviewed in person in the clinic or by
phone by either a psychologist (AS) or a psychiatrist
(SW), using established or previously used stringent diag-
nostic criteria [6,14,16,21,22], reviewed in [20]. The study
was approved by the Ethics Board of the Landesaerzte-
kammer Hessen in Wiesbaden, Germany.
Statistical analysis
We used the Fisher’s Exact Test and unpaired t-tests for
categorical and continuous variables respectively, and
Spearman’s rank test for non-parametric variables
(cigarette, alcohol use) was used with SPSS Version
16.0. Since the factors tested were based on known asso-
ciations with ICBs in Parkinson’s disease, p < 0.05 was
considered significant.
Results
The study tree is shown in Figure 1. Fifty-seven percent
(160/274) of subjects responded to the mail-out question-
naires. Face-to-face clinical interviews or extensive phone
interviews were conducted with 27 subjects who showed
any positive score on the mail-out questionnaires. One-
third (32/114) of the non-responders were randomly
selected for contact by telephone (CT). Subjects commen-
ted that they did not respond to the questionnaires as they
had either never experienced any of these behaviours, felt
irritated by the questions, or did not require treatment for
RLS symptoms at that time.
ICBs were reported in 10/140 (7.1%) respondents after
an extensive interview (Table 1) and 1/32 non-respondents
(compulsive shopping and binge eating) contacted by
phone. Of the responders, compulsive eating was identi-
fied in 6/140 (4.3%), compulsive shopping in 5/140 (3.6%),
pathological gambling in 3/140 (2.1%), punding in 3/140
(2.1%), hypersexuality in 2/140 (1.4%) and compulsive
medication use in none. Subjects with computer gambling
spent money gambling on the Internet and fulfilled criteria
for pathological gambling. Two subjects on levodopa
monotherapy developed compulsive shopping in addition
to comorbid punding in one subject. All patients had ICB
onset after medication initiation, none had previously
been identified as having an ICB.
All ten subjects identified with an ICB were female.
Female-specific prevalence rates were as follows: com-
pulsive eating in 6/98 (6.1%), compulsive shopping in
5/98 (5.1%), pathological gambling in 3/98 (3.1%), pund-
ing in 3/98 (3.1%) and hypersexuality in 2/98 (2.0%).
ICBs were reported in 10% of women who responded to
the questionnaire. Associated factors are reported in
Table 2. All subjects with ICBs received dopaminergic
therapy. In the RLS group without ICBs 122/130 sub-
jects (93.8%) received dopaminergic therapy, 8/130 sub-
jects (6.2%) received only non-dopaminergic medication.
ICBs were associated with higher DA dose, younger age
of RLS onset, history of experimental drug use, female
gender and a family history of gambling disorders
Voon et al. BMC Neurology 2011, 11:117
http://www.biomedcentral.com/1471-2377/11/117
Page 2 of 6
(Table 2). Using a logistic regression analysis, these fac-
tors accounted for 52% of the variance and predicted
ICBs at 42.9%. P-values at model entry were as follows:
DA dose (p = 0.002), experimental drug use (p =<
0.0001), age of RLS onset (p = 0.05), gender (p = 0.12).
The addition of female gender to the model increased
the R2 value from 45 to 52 and was thus included in the
model.
Discussion
ICBs occurred in 7.1% (10/140) of RLS patients treated
with either a DA (8/10) or levodopa monotherapy (2/10).
Eight of ten (80%) subjects had more than one comorbid
ICB. ICBs in RLS patients were associated with higher
levodopa-equivalent DA dose [23], young age of RLS
onset, history of experimental drug use, female gender
and a family history of gambling disorders. These factors
Figure 1 Study tree of 274 RLS patients.
Table 1 Impulse control and compulsive behaviours diagnoses and medication data in patients with restless legs
syndrome
Patient ICB diagnosis DA type/dose L-dopa dose
1 Compulsive shopping, binge eating Ropinirole/2mg 100 mg
2 Computer gambling, hypersexuality Pramipexole/0.72 mg –
3 Binge eating, punding Pramipexole/1.4 mg –
4 Gambling, binge eating Ropinirole/4.5 mg –
5 Compulsive shopping, binge eating Ropinirole/2 mg –
6 Computer gambling, hypersexuality, binge eating Pramipexole/0.95 mg –
7 Compulsive shopping, binge eating Lisuride/2.5 mg –
8 Punding Cabergoline/3 mg
9 Compulsive shopping – 100 mg
10 Compulsive shopping, punding – 500 mg
Voon et al. BMC Neurology 2011, 11:117
http://www.biomedcentral.com/1471-2377/11/117
Page 3 of 6
also accounted for 52% of the variance and predicted
ICBs at 42.9%.
Study strengths include the use of validated or pre-
viously utilized screening questionnaires and established
instruments to assess associated factors, as well as the
use of stringent diagnostic criteria and extensive inter-
views with a psychologist or a psychiatrist. Based on the
identification of ICBs in only 1/32 randomly selected
non-responders (3.1%) we caution that the occurrence of
ICBs in RLS patients found in this study may be over-
estimated, as the experience of behavioural changes may
have motivated the subjects to fill out the questionnaires
and thus bias the results of the study.
One limitation of the study is the lack of a control
group. However, all RLS patients with ICBs were on
dopaminergic therapy and none of the RLS patients
with non-dopaminergic medication was identified with
an ICB. In accordance with previous findings [24-27]
this is supportive of an association between ICBs and
dopaminergic medication in RLS patients. We can also
confirm the previous association between the occur-
rence of ICBs in RLS and treatment with higher dosages
of dopaminergic agents compared to RLS patients who
did not develop ICBs [24,26]. As depression may present
an individual susceptibility factor for abnormal beha-
viours in PD patients [28] and neuropsychological test-
ing revealed preserved executive functions in a previous
study on PD patients with pathological gambling [29],
the lack of further psychiatric and neuropsychological
evaluation in our cohort further limits the study pre-
sented here. Comparative assessment of psychiatric
comorbidities and cognitive profiles should be addressed
in further studies.
Compulsive eating was identified in 6/140 (4.3%), com-
pulsive shopping in 5/140 (3.6%), pathological gambling
in 3/140 (2.1%), punding in 3/140 (2.1%), hypersexuality
in 2/140 (1.4%) and compulsive medication use in none
of the subjects. These frequencies are relatively similar
to RLS studies conducted in North America [24-27]
although the phenotypes of ICB are different compared
to US patient cohorts. One study compared 100 RLS
treated patients, 275 controls with obstructive sleep
apnoea and 52 RLS untreated patients. RLS patients
on dopaminergic medications had greater pathologic
Table 2 Patient characteristics and factors associated with impulse control and compulsive behaviours in patients with
restless legs syndrome
RLS + ICBs RLSnonICBs p-value
Total number n = 10 n = 130
Female gender n = 10 (100%) n = 88 (67.6%) 0.04
Mean age of RLS onset in years (SD) 46.6 (10.1) 57 (15.9) 0.04
Medication Dopaminergic n = 10 (100%) n = 122 (93.8%) 0.4
Other n = 0 (0%) n = 8 (6.2%)
Da type Ropinirole n = 3 (37.5%) n = 29 (29.8%) 0.6
Pramipexole n = 3 (37.5%) n = 43 (44.3%) 0.5
Other n = 2 (25%) n = 25 (25.7%) 0.3
Mean DA dose as LEDD mg/d *(SD) 63.7 (52.7) 26.7 (26.4) 0.001
FHx alcohol use disorder n = 3 (30%) n = 12 (9.2%) 0.09
FHx gambling disorder n = 2 (20%) n = 2 (2%) 0.02
Hx experimental drug use n = 5 (50%) n = 10 (7.9%) 0.002
Cigarettes smoked daily 0 n = 5 (50%) n = 81 (62.3%) 0.19
1-10 n = 0 (0%) n = 10 (13%)
11-20 n = 3 (30%) n = 13 (10%)
21-29 n = 0 (0%) n = 6 (6%)
> 30 n = 2 (20%) n = 10 (13%)
Alcohol daily glasses 0 n = 8 (80%) n = 70/118 (59.3%) 0.18
1-7 n = 2 (20%) n = 41/118 (34.8%)
8-14 n = 0 (0%) n = 5/118 (4.2%)
15-21 n = 0 (0%) n = 2/118 (1.7%)
> 22 n = 0 (0%) n = 0 (0%)
Mean novelty seeking score (SD) 20.8 (5.3) 18 (5.5) 0.13
*Calculation of Levodopa Daily Dose Equivalent (23); Abbreviations: RLS = Restless Legs Syndrome; ICBs = Impulse control behaviors; SD = standard deviation; DA
= dopamine agonist; LEDD = levodopa dose equivalent; FHx = Family history; Hx = history; cut-off for significance: p < 0.05.
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gambling (5%), compulsive shopping (9%) and punding
(7%) than the sleep apnoea control group along with
greater compulsive shopping relative to the RLS
untreated group [24,26]. Our study uniquely focuses on
ICBs in RLS patients in a European rather than a North
American cohort and further investigates associated
factors. The frequency of ICBs is greater in Parkinson’s
disease compared to RLS and has been suggested to be
related to dose effects [24]. In a large multicentre North
American study focusing on Parkinson’s disease, patholo-
gical gambling is reported in 2.9% (with problem gam-
bling in an additional 2.3%), compulsive shopping in
6.0%, hypersexuality in 3.5%, and binge eating in 3.5%
[10]. Punding has been reported in 1.5 to 14% [12,14]
and compulsive medication use in 3 - 4% [16,30].
In the North American general population, binge eating
disorder is identified in 3.5% of women and 2% of men [31]
and compulsive shopping in 6% [32]. The lifetime preva-
lence of a binge eating disorder in European countries,
including Germany, has been reported to be 1.12% [33].
The lifetime prevalence of pathological gambling in North
America is 1.5% [34] whereas the 2006 German Epidemio-
logical Survey of Substance Abuse (n = 7817, aged 18-64
years old), that was controlled for mania, found a much
lower lifetime prevalence of DSM IV-diagnosis of patholo-
gical gambling at 0.09% [35]. Pathological gambling in
Germany may be lower due to a negative cultural attitude
towards gambling as well as a less widespread access to
casinos. Intriguingly, the rate of pathological gambling in
RLS is similar to the rate reported in PD in North America,
but access to gambling in our study in Germany was
through the Internet. The prevalence rates of binge eating
and compulsive shopping in RLS patients may reflect a dif-
ferent pattern of presentation in females. We did not find
RLS patients with compulsive medication use, which may
be due to the lower frequency and dosage of levodopa use
in Germany.
Associated factors such as a history of experimental drug
use and a family history of gambling disorders are consis-
tent to that observed in the literature on ICBs in Parkin-
son’s disease [10,14,15,17]. Factors such as cigarette and
alcohol use and novelty seeking may reach significance
with a larger sample size. This suggests that a similar bio-
logical predisposition may underlie these behaviours rather
than Parkinson’s disease itself being an absolutely necessary
factor. The young age of RLS onset suggests that geneti-
cally mediated forms of RLS may have a different suscept-
ibility to dopaminergic medications. In Parkinson’s disease,
male gender is considered a risk factor for specific ICBs
such as hypersexuality [36]. In our study only women were
affected by ICBs. Further studies in large cohorts are neces-
sary to clarify whether this is due to the greater overall pre-
valence of RLS in women - as reflected in our study cohort.
None of the RLS patients identified with ICBs in this
study attributed their ICB symptoms to dopaminergic
treatment. Although all affected study subjects were
advised to have their treatment regimen changed, none
felt sufficiently impaired by their behaviours to stop
dopaminergic medications completely, but agreed to a
reduced dosage or combination therapy with non-dopa-
minergic agents.
Conclusions
Higher DA dose, young age of RLS onset, history of
experimental drug use, female gender and a family history
of gambling disorders may be predisposing factors for
developing an ICB in RLS with dopaminergic treatment.
RLS patients should be forewarned of potential beha-
vioural side-effects when treated with dopaminergic agents
and dopamine agonists in particular.
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